Highlights
- Market Cap
- $25.65K
- Enterprise Value
- -$4.12M
- EPS (TTM)
- -$0.55
- Total Revenue (TTM)
- $522.00K
- Gross Profit (TTM)
- $522.00K
- EBITDA (TTM)
- -$10.71M
- Year Range
- $0.00 - $0.42
- ROA (TTM)
- -178.38%
- ROE (TTM)
- -219.69%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Lexaria Bioscience Corp, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Lexaria Bioscience Corp
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -71.43% | -71.43% | |||||||||||
| 2025 | -50.14% | -34.65% | 51.37% | -19.95% | -46.97% | -37.50% | 20.00% | 58.50% | -57.94% | -51.37% | 1.54% | -89.37% | -99.45% |
| 2024 | 2.47% | 73.50% | 87.50% | -34.56% | 51.79% | -45.89% | 38.91% | 25.00% | -34.36% | -23.83% | 14.29% | -4.49% | 69.80% |
| 2023 | 75.04% | -28.57% | 14.20% | 3.66% | -67.27% | 13.58% | 14.09% | -8.41% | -13.05% | -22.41% | 170.79% | 7.14% | 12.53% |
| 2022 | -18.00% | -13.02% | -15.88% | 1.79% | -24.68% | 1.43% | -7.03% | 13.74% | -20.28% | 1.69% | -5.00% | -29.84% | -73.34% |
| 2021 | 76.90% | 4.01% | 22.56% | -6.28% | 33.04% | -15.77% | -8.76% | 9.17% | -16.00% | -0.95% | 6.73% | -32.43% | 41.52% |
Benchmark Metrics
Lexaria Bioscience Corp has an annualized alpha of 389.03%, beta of 0.43, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 13, 2021.
- This stock participated in 250.42% of S&P 500 Index downside but only -97.25% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.43 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 389.03%
- Beta
- 0.43
- R²
- 0.00
- Upside Capture
- -97.25%
- Downside Capture
- 250.42%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Lexaria Bioscience Corp (LEXXW) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lexaria Bioscience Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lexaria Bioscience Corp was 99.96%, occurring on Jan 13, 2026. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.96% | Jun 9, 2021 | 1154 | Jan 13, 2026 | — | — | — |
| -37.29% | Feb 10, 2021 | 19 | Mar 9, 2021 | 63 | Jun 8, 2021 | 82 |
| -26.67% | Jan 22, 2021 | 5 | Jan 28, 2021 | 4 | Feb 3, 2021 | 9 |
| -0.66% | Jan 15, 2021 | 1 | Jan 15, 2021 | 2 | Jan 20, 2021 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lexaria Bioscience Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lexaria Bioscience Corp is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LEXXW relative to other companies in the Biotechnology industry. Currently, LEXXW has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LEXXW in comparison with other companies in the Biotechnology industry. Currently, LEXXW has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |